Replimune Group, Inc. $REPL Shares Bought by Readystate Asset Management LP

Readystate Asset Management LP lifted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 1,296.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,621,012 shares of the company’s stock after acquiring an additional 2,433,292 shares during the quarter. Readystate Asset Management LP’s holdings in Replimune Group were worth $10,982,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. BNP Paribas Financial Markets grew its stake in Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after purchasing an additional 1,879 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Replimune Group during the 2nd quarter valued at approximately $69,000. Tower Research Capital LLC TRC boosted its stake in shares of Replimune Group by 2,020.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock valued at $90,000 after buying an additional 9,235 shares during the last quarter. AlphaQuest LLC grew its position in shares of Replimune Group by 99.9% during the second quarter. AlphaQuest LLC now owns 9,857 shares of the company’s stock worth $92,000 after buying an additional 4,925 shares in the last quarter. Finally, Letko Brosseau & Associates Inc. bought a new stake in shares of Replimune Group in the second quarter worth $100,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Performance

Shares of REPL stock opened at $7.26 on Wednesday. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33. The business has a 50 day moving average of $8.42 and a two-hundred day moving average of $7.38. Replimune Group, Inc. has a 52 week low of $2.68 and a 52 week high of $14.80. The company has a market cap of $599.46 million, a P/E ratio of -2.11 and a beta of 0.73.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.08. As a group, analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current year.

Analyst Ratings Changes

A number of research firms have commented on REPL. Piper Sandler increased their price objective on shares of Replimune Group from $13.00 to $14.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Wedbush increased their price target on shares of Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Replimune Group in a research note on Monday, December 29th. Finally, HC Wainwright raised Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Monday, October 27th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Replimune Group presently has a consensus rating of “Hold” and an average target price of $10.00.

Insiders Place Their Bets

In other news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $11.13, for a total transaction of $111,300.00. Following the completion of the transaction, the chief executive officer owned 333,576 shares in the company, valued at approximately $3,712,700.88. This represents a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kapil Dhingra sold 3,169 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $10.40, for a total transaction of $32,957.60. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 5.20% of the company’s stock.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.